Study guide
20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation
Key Takeaways Explain This Topic AI
Sepsis is defined by Sepsis-3 as life-threatening organ dysfunction caused by a dysregulated host response to infection, diagnosed clinically by an acute increase in total SOFA score ≥ 2 \ge 2 ≥ 2 points.
Septic shock is identified by persistent hypotension requiring vasopressors to maintain MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg AND a serum lactate > 2 mmol/L >2\text{ mmol/L} > 2 mmol/L despite adequate volume resuscitation, with hospital mortality exceeding 40 % 40\% 40% .
Norepinephrine is the first-line vasopressor of choice; vasopressin is the preferred second-line adjunct at a fixed dose of 0.03 units/min 0.03\text{ units/min} 0.03 units/min to treat relative vasopressin deficiency and spare catecholamines.
The Surviving Sepsis Campaign 1-Hour Bundle prioritizes measuring lactate, obtaining blood cultures prior to antimicrobials, administering broad-spectrum IV antibiotics, infusing 30 mL/kg 30\text{ mL/kg} 30 mL/kg balanced crystalloid for hypotension or lactate ≥ 4 mmol/L \ge 4\text{ mmol/L} ≥ 4 mmol/L , and timely vasopressor initiation.
Last updated: October 2026
20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation
Sepsis is a complex, time-critical medical emergency. Understanding the consensus definitions, the hemodynamic categorization of undifferentiated shock, and the evidence-based resuscitation algorithms is central to intensive care and perioperative medicine.
The Sepsis-3 Consensus Definitions (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) eliminated the Systemic Inflammatory Response Syndrome (SIRS) criteria from the formal definition of sepsis, recognizing that SIRS represents an appropriate physiological host response that lacks discriminatory diagnostic validity.
1. Sepsis
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection .
Operational Clinical Definition: Organ dysfunction is identified clinically as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥ 2 \ge 2 ≥ 2 points consequent to an infection.
Baseline Score: The baseline SOFA score is assumed to be zero unless the patient is known to have pre-existing chronic organ dysfunction prior to the acute infection.
Clinical Impact: An acute SOFA increase ≥ 2 \ge 2 ≥ 2 points correlates with an in-hospital mortality rate exceeding 10 % 10\% 10% in the general ICU population.
2. The Sequential Organ Failure Assessment (SOFA) Score
The SOFA score grades dysfunction across six physiological systems from 0 (normal) to 4 (most severe):
Organ System Clinical and Laboratory Variables Graded (0 to 4 Points)
Respiration P a O 2 / F i O 2 ratio (mmHg) P_a\text{O}_2/F_i\text{O}_2\text{ ratio (mmHg)} P a O 2 / F i O 2 ratio (mmHg) (incorporating ventilatory support criteria for scores 3 and 4: ≤ 200 \le 200 ≤ 200 and ≤ 100 mmHg \le 100\text{ mmHg} ≤ 100 mmHg on mechanical ventilation)
Coagulation Platelet count ( × 10 3 / μ L \times 10^3/\mu\text{L} × 1 0 3 / μ L : ≥ 150 \ge 150 ≥ 150 , < 150 <150 < 150 , < 100 <100 < 100 , < 50 <50 < 50 , < 20 <20 < 20 )
Liver Serum bilirubin ( mg/dL \text{mg/dL} mg/dL or μ mol/L \mu\text{mol/L} μ mol/L : < 1.2 <1.2 < 1.2 , 1.2 − 1.9 1.2-1.9 1.2 − 1.9 , 2.0 − 5.9 2.0-5.9 2.0 − 5.9 , 6.0 − 11.9 6.0-11.9 6.0 − 11.9 , ≥ 12.0 \ge 12.0 ≥ 12.0 )
Cardiovascular Mean Arterial Pressure (MAP) and specific vasopressor infusion requirements (dopamine, epinephrine, norepinephrine)
Central Nervous System Glasgow Coma Scale (GCS) score ( 15 15 15 , 13 − 14 13-14 13 − 14 , 10 − 12 10-12 10 − 12 , 6 − 9 6-9 6 − 9 , < 6 <6 < 6 )
Renal Serum creatinine ( mg/dL \text{mg/dL} mg/dL or μ mol/L \mu\text{mol/L} μ mol/L ) or daily urine output ( < 500 mL/day <500\text{ mL/day} < 500 mL/day or < 200 mL/day <200\text{ mL/day} < 200 mL/day )
3. Quick SOFA (qSOFA)
qSOFA is a simplified bedside screening tool developed to prompt clinicians to further investigate for organ dysfunction, initiate therapy, or escalate to intensive care.
Criteria (1 point each; score range 0–3):
- Respiratory Rate: ≥ 22 breaths/min \ge 22\text{ breaths/min} ≥ 22 breaths/min
- Altered Mentation: Glasgow Coma Scale score < 15 <15 < 15
- Systolic Blood Pressure: ≤ 100 mmHg \le 100\text{ mmHg} ≤ 100 mmHg
Interpretation: A qSOFA score of ≥ 2 \ge 2 ≥ 2 identifies non-ICU patients at substantially higher risk of prolonged ICU stay or in-hospital death. Note: Current Surviving Sepsis Campaign (SSC) guidelines recommend against using qSOFA as a single screening tool for sepsis compared to SIRS, NEWS (National Early Warning Score), or MEWS due to its lower sensitivity.
4. Septic Shock
Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone .
Clinical Criteria (Both Required):
Persistent hypotension requiring vasopressors to maintain a MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg ;
Serum lactate level > 2 mmol/L >2\text{ mmol/L} > 2 mmol/L ( > 18 mg/dL >18\text{ mg/dL} > 18 mg/dL ) despite adequate volume resuscitation .
Mortality: In-hospital mortality for patients meeting both criteria exceeds 40 % 40\% 40% (compared to approximately 20 − 25 % 20-25\% 20 − 25% for hypotension alone without hyperlactatemia or hyperlactatemia alone without hypotension).
Differential Diagnosis of Shock: Hemodynamic Profiles
Shock is characterized by widespread cellular dysoxia resulting from an imbalance between systemic oxygen delivery ( D O 2 D\text{O}_2 D O 2 ) and cellular oxygen consumption ( V O 2 V\text{O}_2 V O 2 ).
Hemodynamic Parameter Hypovolemic Shock Cardiogenic Shock Distributive (Septic) Shock Obstructive Shock (Tamponade / PE)
Central Venous Pressure (CVP) Markedly Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Markedly Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased or Normal ( ↓ / ↔ \downarrow / \leftrightarrow ↓ / ↔ ) Markedly Increased ( ↑ ↑ \uparrow\uparrow ↑↑ )
Pulmonary Artery Occlusion Pressure (PAOP) Markedly Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Markedly Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased or Normal ( ↓ / ↔ \downarrow / \leftrightarrow ↓ / ↔ ) Variable ( ↑ \uparrow ↑ in Tamponade; ↓ \downarrow ↓ or normal in PE)
Cardiac Output / Cardiac Index (CO/CI) Decreased ( ↓ \downarrow ↓ ) Markedly Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Increased Early ( ↑ ↑ \uparrow\uparrow ↑↑ ) ; Decreased Late Markedly Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ )
Systemic Vascular Resistance (SVR) Compensatory High ( ↑ ↑ \uparrow\uparrow ↑↑ ) Compensatory High ( ↑ ↑ \uparrow\uparrow ↑↑ ) Severely Low ( ↓ ↓ \downarrow\downarrow ↓↓ ) Compensatory High ( ↑ ↑ \uparrow\uparrow ↑↑ )
Central Venous Oxygen Saturation ( S c v O 2 S_{cv}\text{O}_2 S c v O 2 ) Decreased ( < 65 − 70 % <65-70\% < 65 − 70% ) Markedly Decreased ( < 60 % <60\% < 60% ) Normal to High ( > 70 − 80 % >70-80\% > 70 − 80% ) Decreased ( < 60 − 65 % <60-65\% < 60 − 65% )
Pulse Pressure Narrowed Narrowed Widened (Bounding pulses) Narrowed (Pulsus paradoxus in Tamponade)
Note on Distributive Hemodynamics: The classic hemodynamic profile of early resuscitated septic shock is "warm shock": high cardiac output, bounding arterial pulses, low diastolic pressure, and paradoxically elevated S c v O 2 S_{cv}\text{O}_2 S c v O 2 . Elevated S c v O 2 S_{cv}\text{O}_2 S c v O 2 occurs because inflammatory microvascular endothelial dysfunction leads to microcirculatory shunt, capillary uncoupling, and mitochondrial dysfunction ("cytopathic dysoxia"), preventing peripheral tissues from extracting delivered oxygen.
Surviving Sepsis Campaign: The 1-Hour Bundle
The Surviving Sepsis Campaign bundle represents a set of evidence-based interventions that should be initiated immediately, ideally within 1 hour of sepsis or septic shock recognition. Sepsis or Septic Shock Recognized
- │
- ├── 1. Measure Blood Lactate Level (Remeasure within 2-4 hours if initial > 2 mmol/L)
- ├── 2. Obtain Blood Cultures PRIOR to Starting Antibiotics (Aerobic + Anaerobic sets)
- ├── 3. Administer Broad-Spectrum IV Antimicrobials within 1 Hour
- ├── 4. Rapidly Infuse 30 mL/kg Balanced Crystalloid for MAP < 65 or Lactate >= 4 mmol/L
- └── 5. Initiate Vasopressors (Norepinephrine First-Line) to Maintain MAP >= 65 mmHg
Measure Blood Lactate Level: Remeasure lactate within 2 − 4 hours 2-4\text{ hours} 2 − 4 hours if the initial lactate is > 2 mmol/L >2\text{ mmol/L} > 2 mmol/L . Resuscitation guided by serial lactate clearance (targeting a reduction of ≥ 10 − 20 % \ge 10-20\% ≥ 10 − 20% every 2 hours) is associated with reduced mortality.
Obtain Blood Cultures Prior to Antimicrobial Administration: Collect at least two sets of blood cultures (both aerobic and anaerobic bottles)—one percutaneous set and one from each vascular access device in place > 48 hours >48\text{ hours} > 48 hours . Antimicrobial therapy must never be delayed for difficult venous access if blood cultures cannot be rapidly obtained.
Administer Broad-Spectrum Antimicrobials: The Surviving Sepsis Campaign 2021 guideline recommends empirical antimicrobials within 1 hour for possible septic shock or a high likelihood of sepsis; for possible sepsis without shock, a rapid assessment is followed by antimicrobials within 3 hours if concern persists. Every hour of delay in antibiotic administration correlates with an incremental increase in mortality.
Administer Intravenous Fluid: The guideline suggests about 30 mL/kg 30\text{ mL/kg} 30 mL/kg of intravenous balanced crystalloid within the first 3 hours 3\text{ hours} 3 hours for sepsis-induced hypoperfusion (manifested by MAP < 65 mmHg \text{MAP} < 65\text{ mmHg} MAP < 65 mmHg or serum lactate ≥ 4 mmol/L \ge 4\text{ mmol/L} ≥ 4 mmol/L ).
Crystalloid Selection: Balanced crystalloids (e.g., Plasma-Lyte, Hartmann's solution / lactated Ringer's) are suggested over 0.9 % 0.9\% 0.9% normal saline (a weak recommendation). Large-volume 0.9 % 0.9\% 0.9% saline causes hyperchloremic metabolic acidosis, and the SMART and SALT-ED trials found modestly more major adverse kidney events with saline, although BaSICS and PLUS found no mortality difference.
Fluid Responsiveness: Once initial fluid is delivered, further fluids should be guided by dynamic measures of fluid responsiveness (e.g., passive leg raise [PLR] coupled with continuous cardiac output measurement, stroke volume variation [SVV], or pulse pressure variation [PPV] in mechanically ventilated patients with closed chests and no arrhythmias), rather than static pressures (CVP).
Apply Vasopressors: Initiate vasopressors during or immediately following fluid resuscitation if the patient remains hypotensive, titrating to a target MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg .
Vasoactive Drug Algorithm in Septic Shock
Vasoactive Agent Receptor Profile Mechanism and Hemodynamic Action Clinical Role in Sepsis Resuscitation
Norepinephrine α 1 ≫ β 1 \alpha_1 \gg \beta_1 α 1 ≫ β 1 (minimal β 2 \beta_2 β 2 ) Potent peripheral vasoconstriction; restores venous capacitance and tone, increasing preload and MAP with minimal increase in heart rate. First-line vasopressor of choice . Started immediately via peripheral or central venous access.
Vasopressin V 1 V_1 V 1 (vascular smooth muscle), V 2 V_2 V 2 (renal collecting duct) Non-adrenergic vasoconstrictor via G q G_q G q -coupled V 1 V_1 V 1 receptors; restores tone in catecholamine-resistant vascular beds. Second-line add-on agent at a fixed, un-titrated dose of 0.03 units/min 0.03\text{ units/min} 0.03 units/min . Added to norepinephrine to spare catecholamine dose and reduce tachycardia/dysrhythmias.
Epinephrine β 1 = β 2 > α 1 \beta_1 = \beta_2 > \alpha_1 β 1 = β 2 > α 1 at low dose; α 1 > β 1 > β 2 \alpha_1 > \beta_1 > \beta_2 α 1 > β 1 > β 2 at high dose Potent inotrope, chronotrope, and systemic vasoconstrictor; accelerates aerobic glycolysis via β 2 \beta_2 β 2 agonism. Third-line agent added to norepinephrine and vasopressin in refractory shock. Can cause transient hyperlactatemia from β 2 \beta_2 β 2 -stimulated aerobic glycolysis in skeletal muscle.
Dobutamine β 1 > β 2 \beta_1 > \beta_2 β 1 > β 2 (weak α 1 \alpha_1 α 1 ) Potent inotrope and mild peripheral vasodilator; augments cardiac index and tissue perfusion in myocardial dysfunction. Indicated when myocardial dysfunction is present (elevated filling pressures with low cardiac index) or in persistent hypoperfusion despite adequate MAP and fluid.
Phenylephrine Pure α 1 \alpha_1 α 1 agonist Pure peripheral vasoconstriction without direct inotropic or chronotropic activity; increases afterload. Restricted use; reserved only when norepinephrine causes severe tachydysrhythmias or as temporary salvage. May decrease stroke volume.
Dopamine Dose-dependent: D 1 D_1 D 1 ( 1 − 3 mcg/kg/min 1-3\text{ mcg/kg/min} 1 − 3 mcg/kg/min ); β 1 \beta_1 β 1 ( 3 − 10 mcg/kg/min 3-10\text{ mcg/kg/min} 3 − 10 mcg/kg/min ); α 1 \alpha_1 α 1 ( > 10 mcg/kg/min >10\text{ mcg/kg/min} > 10 mcg/kg/min ) Precursor to norepinephrine; stimulates dopamine, β \beta β , and α \alpha α receptors. Not recommended . Meta-analyses and the SOAP II trial demonstrated significantly higher rates of tachyarrhythmias and increased mortality compared to norepinephrine.
Corticosteroid Therapy in Septic Shock
Mechanism: Sepsis often induces critical illness-related corticosteroid insufficiency (CIRCI), characterized by hypothalamic-pituitary-adrenal (HPA) axis dysfunction, suppression of ACTH release, and peripheral glucocorticoid receptor down-regulation. Exogenous corticosteroids restore vascular α 1 \alpha_1 α 1 -adrenergic receptor responsiveness to catecholamines and suppress pro-inflammatory cytokine transcription via nuclear factor-kappa B ( N F - κ B NF\text{-}\kappa B NF - κ B ) inhibition.
Clinical Indication: Intravenous hydrocortisone is recommended only in patients with septic shock who have an ongoing requirement for vasopressor therapy (e.g., norepinephrine or epinephrine dose ≥ 0.25 mcg/kg/min \ge 0.25\text{ mcg/kg/min} ≥ 0.25 mcg/kg/min for at least 4 hours 4\text{ hours} 4 hours ) despite adequate fluid resuscitation.
Dosing Regimen: 200 mg/day 200\text{ mg/day} 200 mg/day of intravenous hydrocortisone , administered either as a continuous infusion ( 8.3 mg/hour 8.3\text{ mg/hour} 8.3 mg/hour ) or as 50 mg 50\text{ mg} 50 mg intravenous boluses every 6 hours.
Trial Evidence:
APROCCHSS Trial (2018): In severe septic shock, hydrocortisone plus fludrocortisone significantly lowered 90-day all-cause mortality ( 43.0 % 43.0\% 43.0% vs 49.1 % 49.1\% 49.1% , p = 0.03 p = 0.03 p = 0.03 ) and shortened the duration of shock.
ADRENAL Trial (2018): Hydrocortisone infusion in septic shock accelerated shock resolution and reduced the duration of mechanical ventilation and ICU stay, though 90-day all-cause mortality was not significantly changed.
Clinical Pearls and Exam Traps
The Sepsis-3 SIRS Trap: SIRS criteria (fever, tachycardia, tachypnea, leukocytosis) are no longer used to define sepsis. SIRS can be triggered by non-infectious insults (e.g., trauma, burns, acute pancreatitis, bypass surgery). Sepsis strictly requires an infection plus an acute increase in SOFA score ≥ 2 \ge 2 ≥ 2 points.
Understanding Hyperlactatemia: Serum lactate elevation in septic shock is not simply a marker of anaerobic metabolism secondary to macrovascular hypoperfusion. A major contributor is stress-induced β 2 \beta_2 β 2 -adrenoceptor stimulation (endogenous epinephrine surge), which up-regulates skeletal muscle sodium-potassium pumps ( N a + / K + Na^+/K^+ N a + / K + -ATPase), accelerates glycolysis, and produces pyruvate exceeding the handling capacity of pyruvate dehydrogenase. Concurrently, hepatic lactate clearance is impaired.
Blood Culture Timing: Never postpone antimicrobial administration beyond 1 hour if blood cultures cannot be obtained due to difficult vascular access.